158 related articles for article (PubMed ID: 20890703)
1. Cytotoxic effect of clodronate and zoledronate on the chondrosarcoma cell lines HTB-94 and CAL-78.
Streitbuerger A; Henrichs M; Ahrens H; Lanvers-Kaminzky C; Gouin F; Gosheger G; Hardes J
Int Orthop; 2011 Sep; 35(9):1369-73. PubMed ID: 20890703
[TBL] [Abstract][Full Text] [Related]
2. In vitro toxicity of bisphosphonates on human neuroblastoma cell lines.
Vorotnjak M; Boos J; Lanvers-Kaminsky C
Anticancer Drugs; 2004 Sep; 15(8):795-802. PubMed ID: 15494642
[TBL] [Abstract][Full Text] [Related]
3. Bisphosphonates: restrictions for vasculogenesis and angiogenesis: inhibition of cell function of endothelial progenitor cells and mature endothelial cells in vitro.
Ziebart T; Pabst A; Klein MO; Kämmerer P; Gauss L; Brüllmann D; Al-Nawas B; Walter C
Clin Oral Investig; 2011 Feb; 15(1):105-11. PubMed ID: 20024592
[TBL] [Abstract][Full Text] [Related]
4. Preclinical evidence for nitrogen-containing bisphosphonate inhibition of farnesyl diphosphate (FPP) synthase in the kidney: implications for renal safety.
Lühe A; Künkele KP; Haiker M; Schad K; Zihlmann C; Bauss F; Suter L; Pfister T
Toxicol In Vitro; 2008 Jun; 22(4):899-909. PubMed ID: 18325729
[TBL] [Abstract][Full Text] [Related]
5. Bisphosphonates induce apoptosis in human breast cancer cell lines.
Senaratne SG; Pirianov G; Mansi JL; Arnett TR; Colston KW
Br J Cancer; 2000 Apr; 82(8):1459-68. PubMed ID: 10780527
[TBL] [Abstract][Full Text] [Related]
6. The influence of bisphosphonates on viability, migration, and apoptosis of human oral keratinocytes--in vitro study.
Pabst AM; Ziebart T; Koch FP; Taylor KY; Al-Nawas B; Walter C
Clin Oral Investig; 2012 Feb; 16(1):87-93. PubMed ID: 21225298
[TBL] [Abstract][Full Text] [Related]
7. Is zoledronate toxic to human periodontal fibroblasts?
Agis H; Blei J; Watzek G; Gruber R
J Dent Res; 2010 Jan; 89(1):40-5. PubMed ID: 19948943
[TBL] [Abstract][Full Text] [Related]
8. In vitro cytotoxicity of zoledronate (nitrogen-containing bisphosphonate: NBP) and/or etidronate (non-NBP) in tumour cells and periodontal cells.
Tanaka Y; Nagai Y; Dohdoh M; Oizumi T; Ohki A; Kuroishi T; Sugawara S; Endo Y
Arch Oral Biol; 2013 Jun; 58(6):628-37. PubMed ID: 23245859
[TBL] [Abstract][Full Text] [Related]
9. Osteonecrosis of the jaw: effect of bisphosphonate type, local concentration, and acidic milieu on the pathomechanism.
Otto S; Pautke C; Opelz C; Westphal I; Drosse I; Schwager J; Bauss F; Ehrenfeld M; Schieker M
J Oral Maxillofac Surg; 2010 Nov; 68(11):2837-45. PubMed ID: 20971371
[TBL] [Abstract][Full Text] [Related]
10. Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis.
Daubiné F; Le Gall C; Gasser J; Green J; Clézardin P
J Natl Cancer Inst; 2007 Feb; 99(4):322-30. PubMed ID: 17312309
[TBL] [Abstract][Full Text] [Related]
11. Bisphosphonates inhibit cell functions of HUVECs, fibroblasts and osteogenic cells via inhibition of protein geranylgeranylation.
Hagelauer N; Ziebart T; Pabst AM; Walter C
Clin Oral Investig; 2015 Jun; 19(5):1079-91. PubMed ID: 25261400
[TBL] [Abstract][Full Text] [Related]
12. Vγ9Vδ2 T cells and zoledronate mediate antitumor activity in an orthotopic mouse model of human chondrosarcoma.
Sun L; Li Y; Jiang Z; Zhang J; Li H; Li B; Ye Z
Tumour Biol; 2016 Jun; 37(6):7333-44. PubMed ID: 26676633
[TBL] [Abstract][Full Text] [Related]
13. Inhibitory effects of a new bisphosphonate, minodronate, on proliferation and invasion of a variety of malignant bone tumor cells.
Kubo T; Shimose S; Matsuo T; Tanaka K; Yasunaga Y; Sakai A; Ochi M
J Orthop Res; 2006 Jun; 24(6):1138-44. PubMed ID: 16705696
[TBL] [Abstract][Full Text] [Related]
14. Antitumoral and antiangiogenic efficacy of bisphosphonates in vitro and in a murine RENCA model.
Soltau J; Zirrgiebel U; Esser N; Schächtele C; Totzke F; Unger C; Merfort I; Drevs J
Anticancer Res; 2008; 28(2A):933-41. PubMed ID: 18507039
[TBL] [Abstract][Full Text] [Related]
15. Bisphosphonate-induced ATP analog formation and its effect on inhibition of cancer cell growth.
Mönkkönen H; Kuokkanen J; Holen I; Evans A; Lefley DV; Jauhiainen M; Auriola S; Mönkkönen J
Anticancer Drugs; 2008 Apr; 19(4):391-9. PubMed ID: 18454049
[TBL] [Abstract][Full Text] [Related]
16. Zoledronate sensitizes endothelial cells to tumor necrosis factor-induced programmed cell death: evidence for the suppression of sustained activation of focal adhesion kinase and protein kinase B/Akt.
Bezzi M; Hasmim M; Bieler G; Dormond O; Rüegg C
J Biol Chem; 2003 Oct; 278(44):43603-14. PubMed ID: 12933798
[TBL] [Abstract][Full Text] [Related]
17. The effects of bisphosphonates on osteoblasts in vitro.
Naidu A; Dechow PC; Spears R; Wright JM; Kessler HP; Opperman LA
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2008 Jul; 106(1):5-13. PubMed ID: 18504149
[TBL] [Abstract][Full Text] [Related]
18. [Antitumor properties of the bisphosphonate zoledronate and potential therapeutic implications in the clinic].
Clézardin P
Bull Cancer; 2010 Aug; 97(8):937-49. PubMed ID: 20595092
[TBL] [Abstract][Full Text] [Related]
19. Zoledronic acid and clodronate in the treatment of malignant bone metastases with hypercalcaemia; efficacy and safety comparative study.
Sabry NA; Habib EE
Med Oncol; 2011 Jun; 28(2):584-90. PubMed ID: 20204542
[TBL] [Abstract][Full Text] [Related]
20. Zoledronate, ibandronate and clodronate enhance osteoblast differentiation in a dose dependent manner--a quantitative in vitro gene expression analysis of Dlx5, Runx2, OCN, MSX1 and MSX2.
Koch FP; Merkel C; Al-Nawas B; Smeets R; Ziebart T; Walter C; Wagner W
J Craniomaxillofac Surg; 2011 Dec; 39(8):562-9. PubMed ID: 21030265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
